Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in

Maura Pugliatti; Hans-Peter Hartung; Celia Oreja-Guevara; Carlo Pozzilli; Laura Airas; Mona Alkhawajah; Nikolaos Grigoriadis; Melinda Magyari; Bart Van Wijmeersch; Magd Zakaria; Ralf Linker; Andrew Chan; Patrick Vermersch; Thomas Berger

doi:10.3389/fimmu.2022.1045101

Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in

Front Immunol. 2022 Oct 17:13:1045101. doi: 10.3389/fimmu.2022.1045101. eCollection 2022.

Authors

Maura Pugliatti^{1

2}, Hans-Peter Hartung^{3

4

5}, Celia Oreja-Guevara^{6

7}, Carlo Pozzilli⁸, Laura Airas^{9

10}, Mona Alkhawajah^{11

12}, Nikolaos Grigoriadis¹³, Melinda Magyari¹⁴, Bart Van Wijmeersch^{15

16

17}, Magd Zakaria¹⁸, Ralf Linker¹⁹, Andrew Chan²⁰, Patrick Vermersch²¹, Thomas Berger^{22

23}

Affiliations

¹ Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy.
² Interdepartmental Center of Research for Multiple Sclerosis and Neuro-inflammatory and Degenerative Diseases, University of Ferrara, Ferrara, Italy.
³ Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
⁴ Brain and Mind Center, University of Sydney, Sydney, NSW, Australia.
⁵ Department of Neurology, Palacky University Olomouc, Olomouc, Czechia.
⁶ Department of Neurology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
⁷ Faculty of Medicine, Complutense University of Madrid (UCM), Madrid, Spain.
⁸ Multiple Sclerosis Center, S. Andrea Hospital, Department of Human Neuroscience, University Sapienza, Rome, Italy.
⁹ Division of Clinical Neurosciences, University of Turku, Turku, Finland.
¹⁰ Neurocenter of Turku University Hospital, Turku, Finland.
¹¹ Section of Neurology, Neurosciences Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
¹² College of Medicine, Al Faisal University, Riyadh, Saudi Arabia.
¹³ Laboratory of Experimental Neurology and Neuroimmunology, Second Department of Neurology, American Hellenic Educational Progressive Association (AHEPA) University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
¹⁴ Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
¹⁵ Universitair Multiple Sclerosis (MS) Centrum, Hasselt-Pelt, Belgium.
¹⁶ Revalidatie & Multiple Sclerosis (MS), Noorderhart, Pelt, Belgium.
¹⁷ Rehabilitation Research Center (REVAL) & Biomedical Research Institute (BIOMED), Hasselt University, Hasselt, Belgium.
¹⁸ Department of Neurology, Ain Shams University, Cairo, Egypt.
¹⁹ Clinic and Polyclinic for Neurology, Universitätsklinikum Regensburg, Regensburg, Germany.
²⁰ Department of Neurology, Inselspital Bern, Bern University Hospital, University of Bern, Bern, Switzerland.
²¹ University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France.
²² Department of Neurology, Medical University of Vienna, Vienna, Austria.
²³ Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.

Abstract

It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.

Keywords: COVID-19; SARS-CoV-2; adverse events; disease modifying therapies; immune response; multiple sclerosis; vaccines.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 Vaccines
COVID-19* / prevention & control
Humans
Multiple Sclerosis*
SARS-CoV-2
Vaccination

Substances

COVID-19 Vaccines